Johnson & Johnson has sold off its remaining stake in the Kenvue consumer products business it spun off last year. In a filing with the SEC today, J&J said it brought in $3.6 billion for general corporate purposes from the transaction. Johnson & Johnson brought in the cash on May 15 after it issued a…

Johnson & Johnson has announced its first earnings following its decision to rebrand its pharma segment as Johnson & Johnson Innovative Medicine in September. In the third quarter of 2023, the company reported sales growth of 6.8%, amounting to $21.4 billion.  The bestseller for the company was Stelara with sales amounting to $2.864 billion. J&J’s…

Both Johnson & Johnson and Pfizer are gearing up to release third-quarter results. While J&J continues to display resilience with its diverse portfolio, Pfizer continues to face challenges with waning demand for its COVID-19 therapies. To date, Pfizer’s stock is down by roughly a third so far this year, reflecting concerns over its ability to…

A U.S. bankruptcy judge in New Jersey has dismissed a Johnson & Johnson-created company’s bankruptcy filing to resolve talc-related lawsuits. Judge Michael Kaplan’s ruling on July 28 was similar to a U.S. Court of Appeals for the Third Circuit ruling months ago, which failed to find immediate financial distress over the lawsuits. As recounted in…

Johnson & Johnson continues to face legal challenges over allegations that its talcum powder causes cancer. Recently, a judge dismissed the company’s latest attempt to settle thousands of lawsuits through bankruptcy, marking the second time J&J’s bankruptcy strategy has been rebuffed. We take a look at the timeline of the talc litigation below. Johnson &…

Johnson & Johnson (NYSE:JNJ) today reported Q4 results that beat The Street on earnings but missed on revenue amid continued macroeconomic challenges. The company’s Pharmaceutical business saw sales grow 6.8%. Pharma growth drivers included: Darzalex (daratumumab), a biologic for the treatment of multiple myeloma; Stelara (ustekinumab), a biologic for the treatment of a number of…

Johnson & Johnson (NYSE:JNJ) today reported third-quarter results that topped the consensus forecast, with international pharma sales up 2.6% or 9.0% operationally. Drugs fueling growth include Stelara (ustekinumab), Darzalex (daratumumab), Tremfya (guselkumab), Xarelto (rivaroxaban) and Erleada (apalutamide). J&J licensed Darzelex from Genmab. The drug won FDA approval in 2015 for patients with previously treated multiple myeloma. Darzalex…

Johnson & Johnson (NYSE:JNJ) has announced that it will name its consumer health division “Kenvue.” Earlier this year, GSK (NYSE:GSK) made a similar move by naming its consumer healthcare segment “Haleon.” That moniker fuses the old English word ‘hale’ with the name “Leon.” The first word means ‘healthy’ while the second refers to “strength.” Haleon…

A new congressional report concluded that Emergent BioSolutions (NYSE:EBS) attempted to hide evidence related to quality problems before informing the FDA that 15 million COVID-19 vaccines were contaminated. Prepared for Rep. Carolyn Maloney (D-NY) and James E. Clyburn (D-SC), the report from the House and the Select Subcommittee on the Coronavirus Crisis scrutinizes the quality controls in…

On the heels of announcing a $99 million opioid settlement with West Virginia, Johnson & Johnson (NYSE:JNJ) has reached a similar deal worth $77 million with the state of Alabama. The agreement removes J&J from cases filed in the state. The agreement did not involve an admission of liability or wrongdoing. In January, J&J reached…